About EyeGate
EyeGate is a publicly listed company based in Waltham (United States) founded in 1998. It operates as a therapeutics and drug delivery systems for eye diseases are developed. EyeGate has raised $44.47 million across 13 funding rounds from investors including Armistice Capital, Emerge Capital Partners and NiXEN. The company has 12 employees. EyeGate has completed 2 acquisitions, including Jade Therapeutics and Panoptes Pharma. EyeGate offers products and services including Drug Catalog, Special Offers, and Loyalty Programs. Its focus areas include Life Sciences, Drug Delivery, Accessories and Ophthalmology. Its legal entity is KIORA PHARMACEUTICALS, INC. Its competitors include CorneaGen, Cellusion, Avedro, CorNeat Vision and Nu Eyne and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
EyeGate was founded in 1998 as a specialty pharmaceutical company based in Waltham, United States. Operations center on the development and commercialization of therapeutics and drug delivery systems for ocular disorders. The lead candidate, EGP-437, employs a reformulated dexamethasone phosphate delivered via the EyeGate II system. Phase 3 trials are underway for non-infectious anterior uveitis, while proof-of-concept studies address macular edema variants.
- Headquarters Waltham, United States
- Employees 12
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website eyegatepharma.com
- Social LinkedIn
- Legal Name Kiora Pharmaceuticals, Inc.
- Total Equity Funding$44.47M (USD)
in 13 rounds
- Latest Funding Round$10.75M (USD), Post-IPO
Aug 2021
- InvestorsArmistice Capital
& 8 more
- Employee Count12
- Investments & AcquisitionsJade Therapeutics
& 1 more
Products & Services of EyeGate
EyeGate offers a comprehensive portfolio of products and services, including Drug Catalog, Special Offers, and Loyalty Programs.
Platform for purchasing various affordable medications online
Discounted products including bestsellers and weekly deals
Rewards system for repeat purchases and bonuses
Funding Insights of EyeGate
EyeGate has successfully raised a total of $44.47M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10.75 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $44.47M
- Total Rounds 13
- Last Round Post-IPO — $10.75M
- First Round $10M
(Nov 2006)
- Investors Count 9
Latest 10 of 13 funding rounds of EyeGate with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | $10.75M | Post-IPO | – | – | – |
| Jan 2021 | $8M | Post-IPO | – | – | |
| Oct 2019 | $1.88M | Post-IPO | – | – | – |
| Jun 2016 | $3.77M | Post-IPO | – | – | – |
| Mar 2016 | $2.62M | Post-IPO | – | – | – |
| Jul 2014 | $994,843 | Debt – Conventional | – | – | – |
| Sep 2013 | $968,971 | Debt – Conventional | – | – | – |
| Jan 2011 | $5.9M | Series D | – | Emerge Capital Partners, NiXEN | |
| Dec 2009 | $11.08M | Series D | – | – | – |
| Oct 2009 | $490,000 | Series D | – | – | – |
9 investors in total: 9 institutional.
Investors in EyeGate
EyeGate has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Armistice Capital, Emerge Capital Partners and NiXEN.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward France by NiXEN. | – | nixen.com | Paris, France | |
Comprehensive strategic expertise in healthcare is provided by MEDICIS. | 1994 | medicis.de | Munich, Germany | |
- | – | innoven-partners.com | - | |
Early-stage funding is provided to innovative founders by Ventech. | – | ventechvc.com | Paris, France | |
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States | |
Global investment bank | – | emergecap.com | Sydney, Australia | |
Ventech Solutions is engaged in delivering technology transformation services. | – | ventechsolutions.com | Round Rock, United States | |
- | – | nexusmp.com | - | |
Delivers comprehensive data center, network management, and managed security services. | 1994 | nxs.net | Nashville, United States |
Investor details for EyeGate
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EyeGate
22 people are tracked at EyeGate (4 in leadership, 16 in board & advisors, 2 in team); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Claudia Gregorio-King | Senior Director, Clinical Development | Leadership |
Brian Strem | President & CEO | Leadership |
Brenda Mann | VP, R&D | Leadership |
Eric Daniels | Chief Development Officer | Leadership |
Kenneth Gayron | Director | Board & advisors |
Aron Shapiro | Non Executive Director, Board Of Directors | Board & advisors |
Mark Pennesi | Advisor | Board & advisors |
Carmine Stengone | Director | Board & advisors |
Paul Chaney | Chairman | Board & advisors |
David Hollander | Director | Board & advisors |
Erin Parsons | Director | Board & advisors |
Praveen Tyle | Director | Board & advisors |
Daniel Durrie | Advisor | Board & advisors |
Allen C. Ho | Advisor | Board & advisors |
Paul Karpecki | Advisor | Board & advisors |
Victor Perez | Advisor | Board & advisors |
Christine Kay | Advisor | Board & advisors |
Russell Van Gelder | Advisor | Board & advisors |
Francis Mah | Advisor | Board & advisors |
Charlie Wykoff | Advisor | Board & advisors |
2 more people are available in the full profile.
Complete people profiles for EyeGate
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EyeGate
EyeGate has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Jade Therapeutics and Panoptes Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapies are developed for severe eye diseases. | panoptes-pharma.com | Vienna, Austria | 2013 | Dec 2020 | •••• | |
Polymer-based products for ophthalmic drug delivery are developed using iontophoresis. | jadetherapeutics.com | Salt Lake, United States | 2012 | Mar 2016 | •••• |
Complete acquisition details for EyeGate
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of EyeGate
6 dated milestones of EyeGate across 23 years, from founding to its latest funding, stage changes and deals.
- Founded EyeGate is founded.
- Funding First funding round of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Jade Therapeutics.
- Acquisition Acquires Panoptes Pharma.
- Funding Latest funding round, Post-IPO, of $10.8M.
Competitors of EyeGate
EyeGate has 9 listed competitors in our database, 7 of them funded. They include CorneaGen, Cellusion, Avedro, CorNeat Vision and Nu Eyne, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| corneagen.com | 2017 | Seattle, United States | $42M | 205 | Therapeutic devices for corneal transplants are developed by CorneaGen. | |
| cellusion.jp | 2015 | Minato, Japan | $29.71M | – | iPS cell-based technology for corneal endothelium regeneration is developed. | |
| avedro.com | 2007 | Waltham, United States | $210.76M | 113 | Corneal collagen cross-linking technology is developed for ophthalmic applications. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| nueyne.com | 2017 | Seoul, South Korea | – | – | Medical devices using electrical stimulation for health conditions are developed. | |
| eye-yon.com | 2011 | Ness Ziona, Israel | $35.1M | – | Ophthalmic devices for corneal edema treatment are developed. | |
| flex-grip.com | 2011 | Diepenbeek, Belgium | $11M | 2 | Catheter cushions and stabilisation devices are provided for patient safety. | |
| recornea.com | 2019 | Udine, Italy | $161,997 | – | Provider of corneal implants devices for the treatment of eye diseases | |
| biolatticetech.com | 2017 | Philadelphia, United States | – | – | Solutions for tissue repair and restoration are developed. |
Detailed competitors of EyeGate
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EyeGate
The website of EyeGate (eyegatepharma.com) receives about 5.3K visits a month and ranks #2,931,419 among all websites worldwide, #3,918 in Biotechnology and Pharmaceuticals.
- Monthly visits5.3K
▼ 2.5% vs previous month
- Unique visitors2.5K
per month
- Global rank#2,931,419
among all websites
- Category rank#3,918
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit3.1
- Average visit2 min 40 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with EyeGate. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
edgepharma.com | edgepharma.com | 100% | – | #212,309 | – |
arecovpharma.com | arecovpharma.com | 90% | – | #1,530,496 | – |
| viagra.com | 84% | 23.6K | #1,343,902 | View details | |
farmaciasdelnino.mx | farmaciasdelnino.mx | 81% | – | – | – |
| medicinesmexico.com.mx | 75% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for EyeGate
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
10 companies that operate in the same segment as EyeGate (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eyegate
Complete news archive for EyeGate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EyeGate
EyeGate was founded in 1998 and raised its 1st funding round 8 years after it was founded.
EyeGate is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
EyeGate is a funded company, having raised a total of $44.47M across 13 funding rounds to date. The company's 1st funding round was a Series D of $490K, raised on Nov 2006.
EyeGate has 12 employees.
EyeGate was founded in 1998 as a specialty pharmaceutical company based in Waltham, United States. Operations center on the development and commercialization of therapeutics and drug delivery systems for ocular disorders. The lead candidate, EGP-437, employs a reformulated dexamethasone phosphate delivered via the EyeGate II system. Phase 3 trials are underway for non-infectious anterior uveitis, while proof-of-concept studies address macular edema variants.
EyeGate offers Drug Catalog, Special Offers, and Loyalty Programs.
EyeGate has made 2 acquisitions, including Jade Therapeutics, and Panoptes Pharma.
EyeGate has 9 investors. Key investors include Armistice Capital, Emerge Capital Partners, NiXEN, MEDICIS, and Ventech Solutions.
EyeGate operates through Kiora Pharmaceuticals, Inc..